CF
CNO Financial Group, Inc. (CNO)·Q1 2025 Earnings Summary
Executive Summary
- Operating EPS of $0.79 was up 52% year over year; excluding significant items, operating EPS was $0.74, up 42%. GAAP diluted EPS was $0.13, reflecting non-economic market impacts in fixed indexed annuity (FIA) derivative marks and investment valuation changes .
- Revenue was $1.004B, above Wall Street consensus ($975.6M*) and Primary EPS was effectively in line with consensus ($0.79*). Management reaffirmed full-year 2025 guidance including $3.70–$3.90 operating EPS, ~23% tax rate, 19.0–19.4% expense ratio, $200–$250M excess cash flow, and target leverage 25–28% .
- Core insurance product margins remained strong across Annuity, Health, and Life; annuity collected premiums rose 12%, client assets in brokerage/advisory rose 16%, and producing agent count increased 3% year over year .
- Shareholder returns totaled $116.8M (repurchases $99.9M; dividends $16.9M) in Q1; the Board subsequently increased the quarterly dividend to $0.17 (13th consecutive annual increase) .
- Call catalysts: accounting headwind in fee income from Medicare Advantage (MA) mix timing under ASC 606 (cash flows healthy); continued buyback appetite given liquidity; RBC variability explained by FIA option mark-to-market timing; guidance reaffirmation amid macro uncertainty .
What Went Well and What Went Wrong
What Went Well
- Operating earnings strength: Operating EPS $0.79 (+52% YoY); excluding significant items $0.74 (+42% YoY), supported by insurance product margins and improved book yield/new money rates (6.43%) .
- Distribution and production: Annuity collected premiums up 12% (seventh consecutive quarter of growth), client assets in brokerage/advisory up 16%, producing agent count up 3% YoY (ninth consecutive quarter) .
- Management tone: “Our first quarter results enable us to reaffirm our full-year 2025 and three-year ROE guidance… Operating earnings per share excluding significant items were up 42%” – CEO Gary Bhojwani .
What Went Wrong
- GAAP EPS compression: GAAP diluted EPS fell to $0.13 due to non-economic accounting impacts (changes in fair value of embedded derivatives and market risk benefits, investment valuation) versus $1.01 in 1Q24 .
- Fee income headwind: Fee income declined ($-0.8M) from timing under ASC 606 for MA policies as sales mix shifted toward carriers with constrained lifetime revenue recognition; management expects future period reversals as experience builds .
- Stat capital variability: RBC ratio dipped to 379% on timing factors (non-admitted assets) and FIA option mark-to-market dynamics when equities fell; CFO explained economic hedge efficacy and expected reversals .
Financial Results
Q1 2025 vs consensus (S&P Global):
Values retrieved from S&P Global.*
Segment margins:
KPIs and balance sheet indicators:
Non-GAAP adjustments in Q1 2025: Out-of-period favorable reserve adjustment ($6.8M) benefited Life margin, contributing $0.05 to net operating income per diluted share .
Guidance Changes
Earnings Call Themes & Trends
Management Commentary
- CEO Gary Bhojwani: “Operating earnings per diluted share were $0.79, up 52%… Our first quarter results enable us to reaffirm our full year 2025 and 3-year ROE guidance” .
- CFO Paul McDonough on fee income: “Under ASC 606… we apply a constraint with newer carriers… increase in percentage of sales with other carriers drove the decline in fee income… we would see a reversal in some future period” .
- CFO on capital: “We’re inclined to continue to lean in… $250 million of cash at holdco… potential for continuation of elevated buybacks” .
- CFO on RBC: “RBC of 379%… increase in non-admitted assets will reverse… FIA option M2M impact when equities decline; economically a near perfect hedge” .
- CEO on Consumer & Worksite: Health NAP up 9%; Medicare Supplement NAP up 24%; MA policies up 42%; Worksite critical illness up 37%; life up 17%; accident up 4% .
Q&A Highlights
- Buybacks: Management remains inclined to continue elevated repurchases given liquidity and capital position .
- Fee income/MA: Detailed explanation of ASC 606 constraints with newer carriers; expectation for partial reversal within 2025 or beyond; reaffirmed FY fee income guidance as small component of total EPS .
- RBC variability: Timing impacts (non-admitted assets, FIA option marks) explained; economic hedge; variability expected in volatile markets .
- D2C life recovery: Expect bounce in spend/sales, with caveat of secular shift to streaming/social; 36% of D2C sales now via web/digital .
- Macro resilience: Middle-income demand seen as relatively resilient through cycles (aging demographics, medical cost inflation) .
- Medicare dynamics: If MA margins tighten, potential shift to Med Supp; CNO well-positioned in either case (manufactures Med Supp; distributes MA) .
Estimates Context
- Q1 2025 outcomes: Primary EPS $0.79 vs consensus $0.7933 (in line); Revenue $1,004.1M vs consensus $975.6M (beat).*
- Implication: Modest top-line beat with in-line EPS given non-GAAP fee timing and FIA derivative valuation impacts; consensus likely to hold near-term with attention on fee revenue cadence and NII trajectory.*
Values retrieved from S&P Global.*
Key Takeaways for Investors
- Earnings quality: Strong operating EPS growth with resilient insurance product margins; GAAP EPS impacted by market marks not reflective of core operations .
- Revenue and NII momentum: New money rates remain above portfolio, supporting book yield and NII; annuity collected premiums and client assets growth underpin forward earnings power .
- Fee accounting noise, not fundamentals: Fee income decline stems from ASC 606 constraints on newer MA carriers; cash flows healthy and reversals expected as experience matures .
- Capital deployment: Elevated buybacks likely to continue given liquidity and target leverage, adding EPS support; dividend increased to $0.17 post-quarter .
- Guidance stability amid macro uncertainty: Reaffirmed FY25 targets (EPS, tax rate, expense ratio, excess cash, RBC, liquidity, leverage) provide a clear framework; watch FIA option mark-to-market for interim RBC volatility .
- Tactical trading: Near-term stock moves likely tied to MA fee recognition cadence and market-driven derivative marks; constructive bias given core margin strength, buybacks, and guidance reaffirmation .
- Medium-term thesis: Demographic tailwinds, distribution breadth (Consumer + Worksite), and investment portfolio discipline support sustainable ROE improvement through 2027 .
Additional context: Optavise launched “Optavise Clear,” enhancing advocacy and technology for Worksite clients—supports fee-based services and cross-sell opportunities .